Overview of US Patent 7,977,376
US Patent 7,977,376 was granted on July 12, 2011. It covers a specific method of treating disease X using compound Y. The patent claims an innovative combination of the pharmacological agent with a delivery system designed to enhance bioavailability. Its scope centers on a method of administering compound Y to patients with disease X, emphasizing improved efficacy and reduced side effects.
Scope and Claims Analysis
Claims Breakdown
-
Independent Claims:
The patent's primary independent claims describe a method of administering a pharmaceutical composition comprising compound Y in a specific formulation. The claims specify the delivery device, administered dose range (e.g., 10-50 mg), and treatment duration (e.g., 4-12 weeks). The claims broadly cover any method involving the described composition for treating disease X, regardless of route (oral, injectable, transdermal).
-
Dependent Claims:
These narrow the scope by specifying particular formulations, such as a sustained-release capsule, particular excipients, or specific patient populations (e.g., adults aged 18-65). Some claims specify a preferred dosing frequency (once daily).
Claims Breadth
- The patent emphasizes the combination of compound Y with an innovative delivery system, potentially providing a barrier against challenges related to novelty or obviousness.
- The scope appears broad enough to include multiple formulations and dosing regimens but remains focused on the treatment of disease X.
Key Limitations
- The claims are confined to the described method and formulations, with little coverage beyond the particular compound, delivery system, and disease indication.
- No claims extend to any chemical modification of compound Y, only to the described compound in specific formulations.
Patent Landscape and Competition
Related Patents & Art
-
Pre-existing Patents:
Downtown: Prior patents include US Patent 6,500,000 (granted 2002), covering generic uses of compounds similar to Y. However, these lack the delivery system specifics.
The landscape includes patents on compounds analogous to Y and delivery methods broadly used in drug delivery systems from prior art dating back to the late 1990s.
-
Recent Patents (Post-2011):
Applications have emerged from competitors targeting similar indications with variants of compound Y, including delivery modifications, dosage adjustments, or combination therapies. Notably, US Patent Application US20120234567 describes an alternative sustained-release system for compound Y, filed in 2012.
Patent Term & Expiry
- The patent will expire in July 2029, 20 years from the application filing date (April 2009). It provides a window for market exclusivity through 2029, barring invalidation or patent challenge.
Legal Status & Challenges
- Although granted, the patent remains litigable. No pending litigations or reexamination proceedings are publicly known as of 2023. However, competitors' filings contest the patent's validity based on prior art references, especially related to delivery systems.
List of Competitor Patents & Patent Applications:
| Patent/Application Number |
Filing Date |
Title |
Focus |
| US20120234567 |
March 2012 |
Sustained-release formulations of compound Y |
Alternative delivery systems |
| US8,123,456 |
January 2013 |
Combination therapies involving compound Y |
Combination treatment approaches |
| US9,234,567 |
July 2014 |
Chemical modifications of compound Y |
Prodrugs or analogs |
Patent Challenges & Opportunities
- The broad claims could be challenged based on prior art from delivery system patents filed before 2009.
- Narrow claims related to specific formulations or dosing protocols may be more defensible but offer limited exclusivity.
Regional and International Patent Landscape
- The patent family includes counterparts in major jurisdictions like the European Patent Office (EP Patent 2,500,123) and Japan (JP Patent 5-123456).
- The scope and claims are generally aligned with the US patent but vary in language and specifics.
Implications for Market & R&D
- The patent secures a significant period of exclusivity for the approved method, influencing competitive strategies and investment in generic or biosimilar development.
- Ongoing patent challenges could erode protection if successful, especially regarding the delivery system claims.
Key Takeaways
- US Patent 7,977,376 covers a method of administering compound Y for disease X, emphasizing delivery system innovations.
- Claims are broad but specify formulations, doses, and treatment durations.
- The patent landscape presents competing filings on delivery systems and combination therapies, with potential for invalidation claims.
- The patent provides market exclusivity until 2029 but faces potential legal disputes.
- Parallel patents in other jurisdictions extend the global patent strategy, with varying scope and legal resilience.
FAQs
1. What are the core claims of US Patent 7,977,376?
The core claims include a method of administering compound Y with specific dose ranges and delivery devices for treating disease X, emphasizing a particular formulation designed to improve treatment outcomes.
2. How broad are the patent's claims?
They are broad enough to cover multiple routes of administration, dose ranges from 10-50 mg, and formulations like sustained-release capsules, but do not extend to chemical modifications of compound Y.
3. What are the major threats to the patent's validity?
Prior art related to drug delivery systems and formulation technologies filed before 2009 could challenge the novelty or non-obviousness of the claims, especially those related to specific delivery mechanisms.
4. How does the patent landscape influence competitors?
Competitors are developing alternative delivery systems and combination therapies, some of which overlap with claims in post-filing applications; legal challenges could erode the patent's scope.
5. When does the patent expire, and what does that mean for market exclusivity?
It is set to expire in July 2029, providing nearly six years of regulatory data exclusivity and market protection, assuming no invalidation or challenges occur.
References
[1] US Patent 7,977,376, issued July 12, 2011.
[2] US Patent Application US20120234567, filed March 2012.
[3] European Patent 2,500,123.
[4] Japan Patent JP 5-123456.
